$0.63
0.48% yesterday
Nasdaq, Sep 04, 10:01 pm CET
ISIN
IE00BF3W0Q35
Symbol
ITRM

Iterum Therapeutics Plc Stock price

$0.63
-0.08 11.46% 1M
-0.72 53.19% 6M
-1.14 64.29% YTD
-0.42 40.09% 1Y
-1.81 74.10% 3Y
-8.29 92.92% 5Y
-192.12 99.67% 10Y
-192.12 99.67% 20Y
Nasdaq, Closing price Thu, Sep 04 2025
+0.00 0.48%
ISIN
IE00BF3W0Q35
Symbol
ITRM
Industry

Key metrics

Basic
Market capitalization
$28.1m
Enterprise Value
$47.6m
Net debt
$19.5m
Cash
$13.0m
Shares outstanding
42.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | 5.9
EV/Sales
- | 10.0
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-9.2%
Return on Equity
612.6%
ROCE
-62.5%
ROIC
-91.9%
Debt/Equity
-8.4
Financials (TTM | estimate)
Revenue
$0.0 | $4.8m
EBITDA
$-16.8m | $-14.8m
EBIT
$-17.8m | $-13.8m
Net Income
$-24.1m | $-16.1m
Free Cash Flow
$-14.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
54.9% | 21.0%
EBIT
53.5% | 27.5%
Net Income
15.1% | 35.6%
Free Cash Flow
65.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -310.7%
EBIT
-
Net
- | -338.5%
Free Cash Flow
-
More
EPS
$-0.6
FCF per Share
$-0.3
Short interest
3.5%
Employees
9
Rev per Employee
$0.0
Show more

Is Iterum Therapeutics Plc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Iterum Therapeutics Plc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Iterum Therapeutics Plc forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Iterum Therapeutics Plc forecast:

Buy
88%
Hold
13%

Financial data from Iterum Therapeutics Plc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs 0.94 0.94
-
-
-0.94 -0.94
-
-
- Selling and Administrative Expenses 11 11
43% 43%
-
- Research and Development Expense 6 6
80% 80%
-
-17 -17
55% 55%
-
- Depreciation and Amortization 0.96 0.96
8% 8%
-
EBIT (Operating Income) EBIT -18 -18
53% 53%
-
Net Profit -24 -24
15% 15%
-

In millions USD.

Don't miss a Thing! We will send you all news about Iterum Therapeutics Plc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Iterum Therapeutics Plc Stock News

Neutral
GlobeNewsWire
16 days ago
FDA-approved antibiotic with the power of a penem in a novel oral formulation, offering a vital alternative in treating uncomplicated urinary tract infections FDA-approved antibiotic with the power of a penem in a novel oral formulation, offering a vital alternative in treating uncomplicated urinary tract infections
Neutral
The Motley Fool
about one month ago
ITRM Reports Results
Neutral
Seeking Alpha
about one month ago
Iterum Therapeutics plc (NASDAQ:ITRM ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Corey N. Fishman - President, CEO & Director Judith M.
More Iterum Therapeutics Plc News

Company Profile

Iterum Therapeutics Plc is a pharmaceutical company which engages in the development and commercialization of sulopenem to be potentially the first and only oral and intravenous (IV) branded penem available. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. It operates through the Ireland and Unites States geographical segments. The company was founded by Corey N. Fishman on June 24, 2015 and is headquartered in Dublin, Ireland.

Head office Ireland
CEO Corey Fishman
Employees 9
Founded 2015
Website www.iterumtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today